ClinicalTrials.gg
CompletedNCT03018054Updated Oct 4, 2019

Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis

A Phase 2 interventional study of E6007 and Placebo in Moderate Active Ulcerative Colitis, sponsored by EA Pharma Co., Ltd.. Completed at 64 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2019-10-04.

Sponsored by EA Pharma Co., Ltd. (part of Eisai Co., Ltd.) · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
20 Years to 74 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of E6007 once daily for 8 weeks in Japanese participants with moderate active ulcerative colitis. Participants will be stratified by prior therapeutic treatment and Mayo score at Baseline, and will be randomized 1:1:1 to receive E6007 30 milligrams (mg), E6007 60 mg or placebo.

02

Conditions studied

  • Moderate Active Ulcerative Colitis

Browse trials for

Keywords

  • moderate active ulcerative colitis
  • Japanese
03

In context

Colitis, Ulcerative

1,853 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

This study's enrollment of 147 is above the median of 70 across 1,236 interventional studies indexed under Colitis, Ulcerative.

Browse Colitis, Ulcerative studies →

Lead sponsor

EA Pharma Co., Ltd. is the lead sponsor of 13 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese participants aged from 20 to 74 years at the time of
  • Participants with a diagnosis based on the Revised Diagnostic Criteria for Ulcerative Colitis (UC) issued by the Research Group for Intractable Inflammatory Bowel Disease Designated as Specified Disease by the Ministry of Health, Labor and Welfare of Japan (2013) at least 4 weeks before the start of administration of study drug
  • Active UC participants as determined by Baseline complete Mayo score of 6 to 10 points with an endoscopic subscore of ≥2 and a rectal bleeding subscore of ≥1
  • Participants who are currently being treated with oral 5-ASA or immunomodulator or with inadequate response or intolerance, or are corticosteroid dependent
  • Participants being seen on an outpatient basis
  • Has voluntarily consented, in writing, to participate in this study and is able and willing to comply with the requirements of this study protocol

Exclusion criteria

Exclusion Criteria:

  • Reduction in partial Mayo score of ≥3 points at Baseline from Screening
  • Diagnosed with right-sided or segmental colitis, and proctitis from a Baseline endoscopy
  • Received any anti-tumor necrosis factor (TNF) agent for over 2 years, or within 12 weeks prior to Baseline
  • History of colectomy, or planning to have surgery for treatment of UC at Screening or Baseline
  • White blood cell count below 3000/microliters (µL) at Screening
  • History or suspected history of central nervous system disorder found at Screening or Baseline
  • Current complication or suspected or toxic megacolon at Screening or Baseline
  • Prior history or current complication of colonic dysplasia at Screening or Baseline
  • History of any severe drug allergy at Screening or Baseline
  • Received a within 4 weeks prior to Baseline
  • repeatedly above 450 milliseconds (ms) on the (ECG) test at Screening
  • In the case of women: nursing mothers or pregnant women at Screening or Baseline
  • Refusal to use medically suitable (both the participant and the participant's partner) throughout the entire study period, if the participant is a man capable of reproduction or a woman of
  • Female participants who want to become pregnant or male participants whose partners want to become pregnant throughout the entire study period
  • Evidence of disease that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments at Screening or Baseline
  • History of any medical conditions or concomitant medical conditions that in the opinion of the investigator(s) would compromise the participant's ability to safely complete the study at Screening or Baseline
  • A positive finding on the antigen and antibody test at Screening
  • In tests conducted at Screening, a positive finding for any of the following: virus surface antigen, hepatitis B virus surface antibody, hepatitis B virus core antibody, or virus antibody
  • Any result other than negative on the tuberculosis test at Screening
  • Findings indicating a history of tuberculosis on chest X-ray during Screening
  • History of drug or alcohol dependency or abuse within approximately the last 2 years prior to Screening or Baseline
  • Use of illegal recreational drugs at Screening or Baseline
  • Currently enrolled in another clinical trial or used any drug or device within 16 weeks preceding
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    E6007 30 mg

    Participants will receive E6007 30 milligrams (mg) once daily after breakfast.

    Drug: E6007

  • Experimental
    E6007 60 mg

    Participants will receive E6007 60 mg once daily after breakfast.

    Drug: E6007

  • Placebo comparator
    Placebo

    Participants will receive matching placebo once daily after breakfast.

    Drug: Placebo

Interventions

  • DrugE6007

    once daily administration

  • DrugPlacebo

    once daily administration

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Mayo score at 8 weeks

    Time frame: Baseline; 8 weeks

Secondary outcomes

  1. Number of participants with abnormal, clinically significant laboratory values

    Time frame: up to 8 weeks

  2. Change from Baseline in body temperature at 8 weeks

    Time frame: Baseline; 8 weeks

  3. Change from Baseline in diastolic blood pressure and systolic blood pressure at 8 weeks

    Time frame: Baseline; 8 weeks

  4. Change from Baseline in heart rate at 8 weeks

    Time frame: Baseline; 8 weeks

  5. Change from Baseline in respiratory rate at 8 weeks

    Time frame: Baseline; 8 weeks

  6. Change from Baseline in standard 12-lead electrocardiogram (ECG) values

    Time frame: Baseline; 8 weeks

  7. Number of participants with abnormal, clinically significant chest X-ray findings

    Time frame: up to 8 weeks

  8. Number of participants with any serious adverse event and number of participants with any non-serious adverse event

    Time frame: up to 8 weeks

07

Study locations

64 sites
  • EA Pharma Trial Site #1
    Nagakute, Aichi, Japan
  • EA Pharma Trial Site #1
    Nagoya, Aichi, Japan
  • EA Pharma Trial Site #2
    Nagoya, Aichi, Japan
  • EA Pharma Trial Site #3
    Nagoya, Aichi, Japan
  • EA Pharma Trial Site #1
    Toyoake, Aichi, Japan
  • EA Pharma Trial Site #1
    Toyota, Aichi, Japan
  • EA Pharma Trial Site #1
    Hirosaki, Aomori, Japan
  • EA Pharma Trial Site #2
    Hirosaki, Aomori, Japan
  • EA Pharma Trial Site #1
    Sakura, Chiba, Japan
  • EA Pharma Trial Site #1
    Urayasu, Chiba, Japan
  • EA Pharma Trial Site #1
    Matsuyama, Ehime, Japan
  • EA Pharma Trial Site #1
    Ogaki, Gifu, Japan
  • EA Pharma Trial Site #1
    Takasaki, Gunma, Japan
  • EA Pharma Trial Site #1
    Fukuyama, Hiroshima, Japan
  • EA Pharma Trial Site #1
    Obihiro, Hokkaido, Japan
  • EA Pharma Trial Site #1
    Sapporo, Hokkaido, Japan
  • EA Pharma Trial Site #2
    Sapporo, Hokkaido, Japan
  • EA Pharma Trial Site #1
    Nishinomiya, Hyogo, Japan
  • EA Pharma Trial Site #1
    Kanazawa, Ishikawa, Japan
  • EA Pharma Trial Site #2
    Kanazawa, Ishikawa, Japan
  • EA Pharma Trial Site #1
    Morioka, Iwate, Japan
  • EA Pharma Trial Site #1
    Takamatsu, Kagawa, Japan
  • EA Pharma Trial Site #2
    Takamatsu, Kagawa, Japan
  • EA Pharma Trial Site #1
    Kamakura, Kanagawa, Japan
  • EA Pharma Trial Site #1
    Kawasaki, Kanagawa, Japan
  • EA Pharma Trial Site #1
    Sagamihara, Kanagawa, Japan
  • EA Pharma Trial Site #1
    Yokohama, Kanagawa, Japan
  • EA Pharma Trial Site #1
    Tsu, Mie, Japan
  • EA Pharma Trial Site #1
    Sendai, Miyagi, Japan
  • EA Pharma Trial Site #2
    Sendai, Miyagi, Japan
  • EA Pharma Trial Site #1
    Nagaoka, Niigata, Japan
  • EA Pharma Trial Site #1
    Kurashiki, Okayama, Japan
  • EA Pharma Trial Site #1
    Osakasayama, Osaka, Japan
  • EA Pharma Trial Site #1
    Suita, Osaka, Japan
  • EA Pharma Trial Site #1
    Kawagoe, Saitama, Japan
  • EA Pharma Trial Site #1
    Izumo, Shimane, Japan
  • EA Pharma Trial Site #1
    Shimotsuga, Tochigi, Japan
  • EA Pharma Trial Site #1
    Bunkyo, Tokyo, Japan
  • EA Pharma Trial Site #1
    Chuo, Tokyo, Japan
  • EA Pharma Trial Site #1
    Hachioji, Tokyo, Japan
  • EA Pharma Trial Site #1
    Minato, Tokyo, Japan
  • EA Pharma Trial Site #2
    Minato, Tokyo, Japan
  • EA Pharma Trial Site #1
    Mitaka, Tokyo, Japan
  • EA Pharma Trial Site #1
    Shinagawa, Tokyo, Japan
  • EA Pharma Trial Site #1
    Shinjuku, Tokyo, Japan
  • EA Pharma Trial Site #1
    Ube, Yamaguchi, Japan
  • EA Pharma Trial Site #1
    Kofu, Yamanashi, Japan
  • EA Pharma Trial Site #1
    Chiba, Japan
  • EA Pharma Trial Site #1
    Fukuoka, Japan
  • EA Pharma Trial Site #2
    Fukuoka, Japan
  • EA Pharma Trial Site #1
    Hiroshima, Japan
  • EA Pharma Trial Site #2
    Hiroshima, Japan
  • EA Pharma Trial Site #1
    Kagoshima, Japan
  • EA Pharma Trial Site #1
    Kumamoto, Japan
  • EA Pharma Trial Site #1
    Kyoto, Japan
  • EA Pharma Trial Site #2
    Kyoto, Japan
  • EA Pharma Trial Site #1
    Nagasaki, Japan
  • EA Pharma Trial Site #1
    Niigata, Japan
  • EA Pharma Trial Site #1
    Okayama, Japan
  • EA Pharma Trial Site #1
    Osaka, Japan
  • EA Pharma Trial Site #2
    Osaka, Japan
  • EA Pharma Trial Site #1
    Saga, Japan
  • EA Pharma Trial Site #2
    Saga, Japan
  • EA Pharma Trial Site #1
    Toyama, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03018054
Responsible party
Sponsor
First posted
Jan 11, 2017
Start date
Nov 28, 2016
Primary completion
Apr 17, 2019
Completion
Aug 16, 2019
Last update
Oct 4, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: E6007

Start the discussion